BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ophthalmic Imaging Systems (OISI) to Restate 2010 and 2009 Quarterly and 2009 Annual Results


3/24/2011 8:47:34 AM

SACRAMENTO, CA--(Marketwire - March 23, 2011) - Ophthalmic Imaging Systems (OIS) (OTCBB: OISI), a leading ophthalmic digital imaging and informatics company, today announced that it will restate its financial results as of and for the fiscal year ended December 31, 2009 included in its Annual Report on Form 10-K, and its interim financial results as filed on Form 10-Q for periods ending March 31, June 30 and September 30, 2010 and 2009. The restatements arise from reclassifying certain warrants issued by the Company in 2007, 2009, and 2010 and embedded conversion option issued in connection with a convertible note issued by the Company in 2007, as liabilities. These warrants and embedded conversion option had been classified as equity.

The adjustments will result in non-cash charges to be reflected below the loss from operations line in the Company's consolidated statements of operations and on the Company's consolidated balance sheet, and will have no impact on the Company's cash balances or loss from operations. Following its evaluation in accordance with guidance provided by SEC Staff Accounting Bulletin No. 108 codified as Topic 1.N, the Company concluded that the impact of the adjustments is quantitatively material to its previously filed financial statements. OIS has discussed this matter with its independent registered public accounting firm, Perry-Smith LLP.

The restated financial results as of and for the fiscal year ended December 31, 2009 will be reported in the Annual Report filed on Form 10-K for the fiscal year ended December 31, 2010. OIS will restate its financial results as of and for the periods ending December 31, 2009, March 31, June 30, and September 30, 2010 and 2009 as soon as practicable.

About Ophthalmic Imaging Systems
Ophthalmic Imaging Systems (www.oisi.com) is the leading provider of ophthalmic digital imaging and informatics systems. The Company designs, develops, manufactures and markets digital imaging systems, image management and integrated EMR and PM solutions for the eye care market. With more than 25 years in the ophthalmic imaging business, the Company has consistently introduced new, innovative technologies. Through its wholly owned subsidiary Abraxas Medical Solutions, Inc., the Company provides EMR and PM software to OB/GYN and orthopedic physicians. The Company markets and supports its products through an extensive network of dealers, distributors and direct representatives.

Statements in this press release that are not historical data are forward-looking statements that involve known and unknown risks, uncertainties, or other factors not under the Company's control, which may cause actual results, performance, or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company's periodic filings with the Securities and Exchange Commission.


Contacts:
Gil Allon
CEO
Ariel Shenhar
CFO
(916) 646-2020

Investor Relations
Jody Cain
Lippert/Heilshorn & Associates
(310) 691-7100

Ophthalmic Imaging Systems
221 Lathrop Way, Suite I
Sacramento, CA 95815


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->